Researchers developed a way to directly reprogram human glial cells into PV interneurons without passing through a stem‑cell stage.

By editing thousands of genes in mouse stem cells, the scientists identified a list of over 300 that are crucial for neural differentiation.

Researchers are continuing to explore how the CXCL13-to-BAFF ratio can be used to advance precision medicine for people with multiple sclerosis.

A personal reflection on the promise and limits of CAR T therapy—its breakthroughs, failures, scientific bottlenecks, and what must change to truly save more lives.

A newly identified and rare genetic variant slows the growth of mutated blood stem cells and reduces the risk of leukemia.

Ultragenyx Pharmaceutical and Mereo BioPharma Group saw their shares plummet after ringing out 2025 by announcing the failures of their brittle bone disease candidate setrusumab (UX143) in a pair of ...

The chip can simulate breathing and lung disease for an individual, holding promise for testing personalized treatments for tuberculosis.

Preclinical AML studies showed palbociclib plus venetoclax produced stronger, more durable anti‑leukemia activity than venetoclax alone and may overcome resistance.

Biopharma may see a happier year ahead in 2026 than in recent years, according to analysts at William Blair. For one thing, the industry’s top stocks have recovered from lows that stretched into last ...

The documents in this eBook provide a glimpse of the kinds of questions asked and answered by researchers using the SomaScan Platform unmatched breakthrough technology.

Study demonstrated that the Homer1 gene improves focus by reducing “noise” in the prefrontal cortex, with implications for studying attention disorders.

In a truly historic decision today, the U.S. Food and Drug Administration (FDA) has, as expected, approved Casgevy, the groundbreaking CRISPR-based gene editing therapy for sickle cell disease (SCD), ...